Literature DB >> 15218027

Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.

Daniel Kirchhofer1, Xiaoyi Yao, Mark Peek, Charles Eigenbrot, Michael T Lipari, Karen L Billeci, Henry R Maun, Paul Moran, Lydia Santell, Christian Wiesmann, Robert A Lazarus.   

Abstract

Hepatocyte growth factor (HGF), a plasminogen-related growth factor, is the ligand for Met, a receptor tyrosine kinase implicated in development, tissue regeneration, and invasive tumor growth. HGF acquires signaling activity only upon proteolytic cleavage of single-chain HGF into its alpha/beta heterodimer, similar to zymogen activation of structurally related serine proteases. Although both chains are required for activation, only the alpha-chain binds Met with high affinity. Recently, we reported that the protease-like HGF beta-chain binds to Met with low affinity (Stamos, J., Lazarus, R. A., Yao, X., Kirchhofer, D., and Wiesmann, C. (2004) EMBO J. 23, 2325-2335). Here we demonstrate that the zymogen-like form of HGF beta also binds Met, albeit with 14-fold lower affinity than the protease-like form, suggesting optimal interactions result from conformational changes upon cleavage of the single-chain form. Extensive mutagenesis of the HGF beta region corresponding to the active site and activation domain of serine proteases showed that 17 of the 38 purified two-chain HGF mutants resulted in impaired cell migration or Met phosphorylation but no loss in Met binding. However, reduced biological activities were well correlated with reduced Met binding of corresponding mutants of HGF beta itself in assays eliminating dominant alpha-chain binding contributions. Moreover, the crystal structure of HGF beta determined at 2.53 A resolution provides a structural context for the mutagenesis data. The functional Met binding site is centered on the "active site region" including "triad" residues Gln(534) [c57], Asp(578) [c102], and Tyr(673) [c195] and neighboring "activation domain" residues Val(692), Pro(693), Gly(694), Arg(695), and Gly(696) [c214-c219]. Together they define a region that bears remarkable resemblance to substrate processing regions of serine proteases. Models of HGF-dependent Met receptor activation are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15218027     DOI: 10.1074/jbc.M404795200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Identification of mannose receptor as receptor for hepatocyte growth factor β-chain: novel ligand-receptor pathway for enhancing macrophage phagocytosis.

Authors:  Hiroyuki Ohnishi; Kiyomasa Oka; Shinya Mizuno; Toshikazu Nakamura
Journal:  J Biol Chem       Date:  2012-02-21       Impact factor: 5.157

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

3.  An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides.

Authors:  Kyle E Landgraf; Micah Steffek; Clifford Quan; Jeffrey Tom; Christine Yu; Lydia Santell; Henry R Maun; Charles Eigenbrot; Robert A Lazarus
Journal:  Nat Chem Biol       Date:  2014-05-25       Impact factor: 15.040

4.  The structure of SHH in complex with HHIP reveals a recognition role for the Shh pseudo active site in signaling.

Authors:  Ivan Bosanac; Henry R Maun; Suzie J Scales; Xiaohui Wen; Andreas Lingel; J Fernando Bazan; Frederic J de Sauvage; Sarah G Hymowitz; Robert A Lazarus
Journal:  Nat Struct Mol Biol       Date:  2009-06-28       Impact factor: 15.369

5.  Structural basis for agonism and antagonism of hepatocyte growth factor.

Authors:  W David Tolbert; Jennifer Daugherty-Holtrop; Ermanno Gherardi; George Vande Woude; H Eric Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

6.  Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor.

Authors:  Toby Passioura; Hiroki Sato; Katsuya Sakai; Kenichiro Ito; Hiroki Furuhashi; Masataka Umitsu; Junichi Takagi; Yukinari Kato; Hidefumi Mukai; Shota Warashina; Maki Zouda; Yasuyoshi Watanabe; Seiji Yano; Mikihiro Shibata; Hiroaki Suga; Kunio Matsumoto
Journal:  Nat Chem Biol       Date:  2019-05-17       Impact factor: 15.040

7.  Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Authors:  Cristina Basilico; Anna Hultberg; Christophe Blanchetot; Natalie de Jonge; Els Festjens; Valérie Hanssens; Sjudry-Ilona Osepa; Gitte De Boeck; Alessia Mira; Manuela Cazzanti; Virginia Morello; Torsten Dreier; Michael Saunders; Hans de Haard; Paolo Michieli
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

8.  A human recombinant IL-7/HGFβ hybrid cytokine enhances antitumor immunity in mice.

Authors:  Feng Han; Rong Hu; Min Su; Yanni Yu; Hua Yang; Laijun Lai
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

9.  Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis.

Authors:  P Goyette; C Lefebvre; A Ng; S R Brant; J H Cho; R H Duerr; M S Silverberg; K D Taylor; A Latiano; G Aumais; C Deslandres; G Jobin; V Annese; M J Daly; R J Xavier; J D Rioux
Journal:  Mucosal Immunol       Date:  2008-01-16       Impact factor: 7.313

10.  Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.

Authors:  Hyori Kim; Jeonghwan Youk; Yaewon Yang; Tae-Yong Kim; Ahrum Min; Hye-Seon Ham; Seongcheol Cho; Kyung-Hun Lee; Bhumsuk Keam; Sae-Won Han; Do-Youn Oh; Han Suk Ryu; Wonshik Han; In Ae Park; Tae-You Kim; Dong-Young Noh; Seock-Ah Im
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-18       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.